Clicky

OPKO Health Inc.(OPK)

Description: Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer's disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; point-of-care diagnostic tests to detect prostate specific antigen; and laboratory developed tests comprising 4Kscore test for the detection of prostate cancer. It also operates OURLab, a full-service medical laboratory specializing in urologic pathology. In addition, the company is developing CTAP101 Capsules to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Fermagate Tablets to treat hyperphosphatemia in end-stage renal disease patients on chronic hemodialysis. Further, it is developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, such as cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate that has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. Additionally, the company develops and produces specialty active pharmaceutical ingredients; offers ophthalmic and other pharmaceutical products; and provides cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones. It operates in the United States, Chile, Mexico, Israel, and Spain. OPKO Health, Inc. is based in Miami, Florida.


Keywords: Cancer Pharmaceutical Products Infectious Diseases Antibiotics Active Pharmaceutical Ingredients Autoimmune Disease Clinical Trial Alzheimer's Disease Chemotherapy Prostate Cancer Influenza Asthma Dialysis Non Small Cell Lung Cancer Phosphates Vitamins Biomarkers Medical Test Kidney Disease Diagnostic Tests Molecular Diagnostics Hemodialysis Pancreatic Cancer Small Cell Lung Cancer Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Ophthalmic Pathology Hormones Thyroid Heart Disease Metabolic Disorders Pulmonary Disease Nausea Renal Disease Medical Laboratory End Stage Renal Disease Heparin Influenza Vaccine Oligonucleotide Cardiovascular Products Organ Failure Stage Renal Disease Hyperparathyroidism Secondary Hyperparathyroidism Hyperphosphatemia Vascular Products Chemotherapy Induced Nausea Opko Health Gastro Intestinal Products OLAP

Home Page: www.opko.com

OPK Technical Analysis

4400 Biscayne Boulevard
Miami, FL 33137
United States
Phone: 305 575 4100


Officers

Name Title
Dr. Phillip Frost Ph.D. Chairman & CEO
Dr. Jane H. Hsiao M.B.A., MBA, Ph.D. Vice Chairman & Chief Technical Officer
Mr. Adam E. Logal Sr. VP, CFO, Chief Accounting Officer & Treasurer
Mr. Steven D. Rubin Esq., J.D. Exec. VP of Admin. & Director
Dr. Jon R. Cohen M.D. Advisor
Dr. Elias Adam Zerhouni M.D. Pres & Vice Chairman
Dr. Arie Gutman Pres of API
Mr. James DeMarco Sr. VP of Pharmaceutical Sales
Dr. Akhtar Ashfaq Sr. VP of Clinical R&D and Medical Affairs
Ms. Jane Pine Wood Esq., J.D. Chief Legal Officer of Bio-Reference Laboratories

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 64.5161
Trailing PE: 0
Price-to-Book MRQ: 0.6119
Price-to-Sales TTM: 0.7916
IPO Date: 1995-11-02
Fiscal Year End: December
Full Time Employees: 5767
Back to stocks